A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.